Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $5.79M | $12.4M | $9.60M | $13.9M | $34.5M | $9.99M | $11.2M |
| Revenue growth | — | 113.6% | -22.4% | 44.3% | 148.9% | -71.0% | 11.7% |
| Operating income | -$34.3M | -$36.1M | -$67.0M | -$106M | -$116M | -$167M | -$148M |
| Operating margin | -592.7% | -292.2% | -697.8% | -768.2% | -336.6% | -1667.2% | -1329.4% |
| Net income | -$23.4M | -$34.3M | -$66.9M | -$99.4M | -$102M | -$149M | -$148M |
| Net margin | -404.8% | -277.6% | -697.3% | -717.8% | -296.1% | -1491.9% | -1327.4% |
| EPS (diluted) | -$2.80 | -$4.01 | -$2.11 | -$1.64 | -$1.38 | -$1.65 | -$1.59 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$32.0M | -$33.2M | -$32.5M | -$91.0M | -$93.3M | -$138M | -$111M |
| Capital expenditures | $884K | $317K | $2.12M | $6.45M | $11.6M | $4.88M | $1.36M |
| Free cash flow | -$32.9M | -$33.5M | -$34.6M | -$97.4M | -$105M | -$143M | -$112M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $41.1M | $16.0M | $240M | $58.3M | $51.2M | $16.3M | $12.4M |
| Total assets | — | $36.0M | $442M | $374M | $432M | $313M | $175M |
| Total liabilities | — | $18.2M | $54.5M | $72.9M | $63.8M | $60.4M | $53.2M |
| Shareholders' equity | $7.46M | -$23.4M | $388M | $301M | $368M | $253M | $122M |
| Retained earnings | — | -$30.9M | -$97.8M | -$197M | -$299M | -$448M | -$597M |
| Shares (wtd avg diluted) | — | 9.71M | 31.7M | 60.8M | 73.8M | 90.3M | 93.4M |
Every figure is extracted from Caribou Biosciences, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.